Patents Assigned to Cognizance Biomarkers, LLC
-
Publication number: 20240151733Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.Type: ApplicationFiled: December 13, 2023Publication date: May 9, 2024Applicant: Cognizance Biomarkers, LLCInventors: Todd WALLACH, Elisa A. WAXMAN, John GLEDHILL, Richard ST. CLAIR, Elizabeth BRAND
-
Patent number: 11885817Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.Type: GrantFiled: May 16, 2018Date of Patent: January 30, 2024Assignee: Cognizance Biomarkers, LLCInventors: Todd Wallach, Elisa A. Waxman, John Gledhill, Richard St. Clair, Elizabeth Brand
-
Publication number: 20240002493Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.Type: ApplicationFiled: May 24, 2023Publication date: January 4, 2024Applicant: Cognizance Biomarkers, LLCInventors: Todd WALLACH, Elisa A. WAXMAN, John GLEDHILL, Richard ST. CLAIR, Elizabeth BRAND
-
Publication number: 20230251276Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computer systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic methods, kits and predictive models provided herein provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.Type: ApplicationFiled: January 30, 2023Publication date: August 10, 2023Applicant: Cognizance Biomarkers LLCInventors: Todd WALLACH, Peter CRINO, John POLLARD, Elizabeth BRAND, Maura STRAUMAN, Christopher HOLLENBEAK, Richard ST. CLAIR, Jeffrey BOTBYL, John GLEDHILL
-
Patent number: 11692030Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.Type: GrantFiled: November 15, 2019Date of Patent: July 4, 2023Assignee: Cognizance Biomarkers, LLCInventors: Todd Wallach, Elisa A. Waxman, John Gledhill, Richard St. Clair, Elizabeth Brand
-
Patent number: 11598782Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computer systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic methods, kits and predictive models provided herein provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.Type: GrantFiled: June 4, 2020Date of Patent: March 7, 2023Assignee: Cognizance Biomarkers, LLCInventors: Todd Wallach, Peter Crino, John Pollard, Elizabeth Brand, Maura Strauman, Christopher Hollenbeak, Rich St. Clair, Jeffrey Botbyl, John Gledhill